Did I read that correctly? They borrowed $75,000. They want to cut deals with space agencies and military branches and they can't write a check for 75k. Sell the patents and close the doors.

They are neck and neck for the best product and worst management in the history of publicly traded companies. ASTI and Mannkind. ASTI has the thinnest, most resiliant solar panels in the world and can't sell them. Mannkind develops the most effective, fastest acting insulin the world has ever seen and nearly goes bankrupt. Who wins?

I initially didn't realize how deeply connected Right to Try and BCLI are, but when you look into it, Matt (the Matthew the President was talking to during the press conference) is Matt Bellina and he's been fighting with ALSA specifically about funding BCLI and making sure this treatment is available fast enough so ALS fast progressors aren't certain to die before FDA approval can be accomplished.

The question now for Brainstorm is can they manage phase 3 and help fast progressors outside the clinical trial at the same time. Maybe City of Hope, the Mayo Clinic and others involved in phase 3 will be able to help.

For me the bottom line is I think their technology works and given it is the patient's own stem cells, not some synthetic drug compound, the risk / reward for ALS patients looks to be in favor of allowing treatment.

Of course, right to try is about more than BCLI and I'm sure there will be some abuses, but for ALS and NurOwn, I think we are looking at a life changing treatment that has proven itself safe in phase 1, 2 and so far in 3.

It's still trading because of the technology...certainly not the competence of the sales staff. Here's a challenge:

Name any solar panel manufacturer that has a better power to weight ratio, better resiliency to damage, absolute thinness and lightness, temperature and pressure ranges (for high altitude & space applications) and as a bonus is manufactured in the USA or one of the USA's military allies?

I know of no company on Earth that produces a panel that exceeds the performance of ASTI's panels for what Lee said is the new focus (military, space, disaster relief, etc.). They are literally the best solar panels on the planet for this type of use. They SHOULD be signing contracts around the world...why they can't do it so far is a mystery.

Can anyone point to a company that produced a better panel for rugged / space / military / disaster relief, drones, lighter than air drones, etc.?

Look in more depth at the results. Different markers diminish at different rates. You're best bet would be to ask the most knowledgable medicial or scientific person you know to look at the data. We amatuers are guessing. Guessing is not the best investment strategy.

Phase 2 was meant to show safety. Although there were measurable medical improvements, a single dose is not how the treatment will be administered when looking for efficacy. That's happening right now in phase 3. If more people get up and walk away from wheelchairs, we've made a great investment. If there is a previously unknown safety issue, severe enough side effect or a lack of efficacy, we made an economically bad investment, but at least it was an investment to bring hope to those suffering with ALS. I'd rather lose money on this than on something like bitcoin.

The articles and videos were from the March / April 2017 timeframe, as you suspected. If they email me back, I'll post the official response. I was digging around trying to determine just how exclusive their patents are on the nanoparticle inks. There was also the military / space application 3D printing circuits embedded in ceramic. The latest, I think, was printing embedded led lighting into automotive plastics, for car interiors and such. They've got quite wide range of capabilities. I think the circuit boards are a great first project to get cashflow to pursue the other projects. If those nano ink patents and other patents are enough to give them a first mover advantage, this could end up being a very good investment. I haven't found a single competitor that can match all of their capabilities yet.

I sent an email to NanoDimension asking if their BioDimension project is owned by NNDM stockholders. I didn't get an answer yet and I'm getting confused by what I've seen in articles. I've read it is a wholly-owned subsidiary, that it is raising it's own money, that it's not officially a separate company because it is unregistered, that they didn't want to risk NNDM shareholder moeny. Do any of you have information about BioDimension?

How much debt do they have and what's their cash burn rate?

In there old investor presentation, they listed $250,000,000 as the total amount invested to get their technology to the point it is now, which is industry leading. Unfortunately, that industry leading technology was pair with what appears to be bad management. However, if you also look at the chart of their former competitors who are now out of business, maybe it was the industry itself that caused some of the unprofitability, due to extremely high competition among vendors.

With a market cap of $8 million and R&D + CapEx over $250 million + the lightest, most flexible, thinnest, most resilient solar panels in the world, they may be able to finally make a profit or more likely, get bought.

Not sure what to make of this. SUNE has, I believe, hundreds of separate wholly or partially owned subsidiaries all over the world. This looks to me like they are selling off one of them. Anyone have more or better info?

BOITIZPOWER International Pte. Ltd. (AP International) signed a share purchase agreement with SunE Solar B.V. (SunE Solar) for the acquisition of 100 percent equity interest in Sunedison Philippines Helios BV (Sunedison Philippines). The offshore execution of the deed of transfer is subject to certain closing conditions under the SPA. In 2014, AboitizPower, through its wholly-owned subsidiary, Aboitiz Renewables, Inc. (ARI), entered into an agreement to develop solar photovoltaic projects in the Philippines. SunEdison Inc. (SUNE), the ultimate parent company of SunE Solar and Sunedison Philippines, and ARI invested in Maaraw Holdings San Carlos, Inc. and San Carlos Sun Power Inc. for the 59-MWp solar project in San Carlos City, Negros Occidental.

Read more: http://www.sunstar.com.ph/cebu/business/2017/12/21/ap-intl-acquires-sunedison-580740
Follow us: @sunstaronline on Twitter | SunStar Philippines on Facebook

I see a mention of MEMC...would you mind educating the newbies as to what this means?

We may have some news about MS entering phase 1. They had a press release with some relatively famous reporter who took the MS treatment and there is video of his good results. Since Brainstorm is using the bodies own stem cells, and their proprietary incubation process allows customization of what the stem cells will produce (neurotrophic factors, etc.), it may be that the results of ALS testing will give more confidence on MS and vice-versa. If they end up having basically conquered all central nervous system diseases, this will be a huge win for humanity and for stockholders.

Of course, things could go the other way as well, but I haven't seen a single negative response from patients in any of the data I can find. Do your own research and let us know if you find anything (positive or negative). I'm more of a tech geek than medical guru, but from what I can tell by the graphs and charts from the other phases of testing, I'm building my share count.

Ralph Kern, M.D., Explains NurOwn as Potential ALS Therapy Moves Through the Pipeline

DECEMBER 08, 2017
Mathew Shanley
This weekend at the International Symposium on ALS/MND in Boston, BrainStorm Cell Therapeutics will be presenting data on their stem cell therapy NurOwn which is currently in development for amyotrophic lateral sclerosis (ALS) and a slew of other neurodegenerative diseases.

The company’s Phase 3 clinical trial is expected to enroll approximately 200 patients and will be conducted at 6 leading ALS clinical sites in the U.S. The first patients were enrolled in mid-October at the Massachusetts General Hospital and University of California Irvine Medical Center in California.

The company expects the study to be fully enrolled by this time next year, and with an additional year of research – 2 years from now – it is expected that there will be topline data.

Rare Disease Report spoke with the company’s Chief Operating Officer and Chief Medical Officer Ralph Kern, M.D. about the potential therapy and why the initiation of the Phase 3 program is so exciting for the ALS community.

RDR: What are BrainStorm’s intentions and goals as they pertain to this Phase 3 of NurOwn?

Kern: We’re an innovative biotechnology company that’s focused on developing cell-based therapies for neurological disease. The unmet need in neurological disease is very great, and that’s primarily because existing treatments offer either symptomatic improvement or modestly slow disease. We are looking at a regenerative medicine approach to neurological disease, with the hope that we can go beyond slowing the disease or providing a therapy that is purely symptomatic. At the end of the day, our goal is that it will translate into benefits for patients in terms of function, ultimately hoping to change the course of the disease.

RDR: What is the technology behind the potential therapy? How is it delivered to the patient?

Kern: Our technology platform is derived from cells that come from the patients themselves, and that’s an important starting point. A patient’s own cells are harvested, they’re purified and processed, and we modify the cells to a cell type that can provide benefit to the diseases that we’re trying to treat. So, cells that are returned to the patients are their own cells that are expanded, modified, and then brought back to deliver a basket of biological molecules that we believe are beneficial to the disease. Just to give a timescale, the technology platform has been in development for 10 years, and this is our seventh year in the ALS clinic.

RDR: Why is it justified for the ALS community to be excited about NurOwn?

Kern: We’re excited for a few reasons: first, in the Phase 2 program, the participants in the study who received a single treatment experienced meaningful clinical improvements. The clinical scale used in ALS is called the ALS Functional Rating Scale and essentially it’s a scale that describes all the things that someone does during the day in 12 different domains; there are 4 points per each subscale, leading to a total score of 48. The way that we measure the outcomes in ALS is to evaluate participants in the run-in period and then after treatment, we measure the score again. We compare before and after changes in ALSFRS-R, and we found in Phase 2 that there was, in a group that was declining at a quicker rate at baseline, an improvement in scores. That’s unusual for this group of ALS patients where, historically, the only observed outcomes have been a continued fast rate of decline. This needs to be confirmed in a larger study, and we plan to study the same group in the Phase 3, and we plan to complete this study as quickly as possible.

RDR: What data specifically is being presented at the International Symposium on ALS/MND?

Kern: We are sharing our biomarker data at ALS/MND in Boston; we have done a lot of research and development on understanding exactly who the cells are, what they do, how they work, and the molecules that they make – even down to the genetic level. We’re able to measure the characteristics of the cells before they’re transplanted and also before and after treatment when the cells are administered by lumbar puncture injection into the spinal fluid. We’ve made interesting observations, both in terms of the molecules that these cells make, but also molecules that indicate progression and state of the disease. That’s why we’re here this week; to show some of the biomarker data at the MND/ALS meeting.

RDR: Why are these biomarkers so important to the future of ALS research?

Kern: The reason that this new information is so important is that the biomarkers may, in the future, tell us which ALS patients might have a greater need for our therapy, may predict disease progression or identify which patients may be expected to have a better response to our therapy. Potentially we may be able to track the biomarkers and adjust treatment accordingly.

These are very exciting times for ALS. We’re testing an advanced cell therapy. We have biomarkers that might help inform that. We’re currently conducting a pivotal Phase 3 program. We hope this will lead to a treatment that ALS patients will be able to access and improve their quality of life.

--

For more information, refer to clinicaltrials.gov (NCT03280056).

Either a DDoS attack, their IT folks screwed up something or they have way too low a limit on their hosting.

Bandwidth Limit Exceeded

The server is temporarily unable to service your request due to the site owner reaching his/her bandwidth limit. Please try again later.

Any thoughts on this?

BETHESDA, MD, December 5, 2017 (GLOBENEWSWIRE) – TerraForm Global, Inc. (Nasdaq: GLBL) (“TerraForm Global” or the “Company”), a global owner and operator of clean energy power plants, today announced that it has exercised its right to extend the termination date under the Agreement and Plan of Merger entered into on March 6, 2017 with certain affiliates of Brookfield Asset Management Inc. (the “Merger Agreement”) from December 6, 2017 to March 6, 2018. However, the closing of the merger is currently anticipated to occur no later than December 29, 2017 on the terms previously approved by the Company’s stockholders at the special meeting held on November 13, 2017.

The technology they developed is not fluff:

monolithically-integrated modules, all on a very thin, 25 micron (0.001 inch) plastic substrate

How many companies on the planet can produce this? You are discounting a quarter of a billion dollars that ASTI's previously incompetent management blew through going after the wrong market. I'm betting they will get military, space and gov't contracts, along with aerospace and drones.

They can stay afloat with the Energizer deal and reverse their fortunes with a single large contract.

Can anyone translate this legalspeak into something a bit more readable:

https://www.natlawreview.com/article/sunedison-court-strikes-down-third-party-releases-multiple-grounds

You're leaving out the assets. Like a quarter of a billion dollars they've spent on developing the product, patents and manufacturing process, their physical assets (building, equipment, etc.)

If they are emerging from bankruptcy without Chap 7 liquidation being the next step, then they have a company strong enough to emerge from bankruptcy.

If they are not emerging from bankruptcy, then we go to Chap 7 and liquidate.

As far as I've heard, they are emerging from Chap 11.

Shareholders who bought before Chap 7 are awaiting multiple lawsuits against SUNE, their executives, whatever the emerged SUNE becomes, Goldman Sachs and other banks and financial backers who lawsuits contend, violated SEC rules.

This saga will be going on for at least another 5 years.

Yes, solar tents with LED lighting built into the central rail. Partner with a water purification company and include a UV lightbulb to purify drinking water. The best thing about the ASTI product is it is light, flexible and durable.

And...in case you were wondering, ASTI is using an outside firm for their investor relations.

We can always ask him to give us an update to what the $%$# they are doing today, tomorrow, next week, month and year to build shareholder value.

Investor Relations
Adam Holdsworth
adamh@pcgadvisory.com
(646) 862-4607

I read the 8K SEC filing and the new CFO, Eyal Rubin has a salary of $16,800 USD / month and was granted 25,000 shares that vest after 1 year. The $300,000 investment on the financial operations side at this early stage in the process of getting their first treatment to market brings up some questions to ponder:

1. Why so early in the process?
a. Are they so confident in eventual success, they want to get started on building their commercial side of the house right away?

b. Does his experience at TEVA indicate that the local choice, TEVA, is going to be the partner that brings a worldwide network of sales and distribution, worldwide regulatory legal experience, PR, etc?

c. Is Eyal going to raise money on the strength of the ALS results to be able to move other trials into Phase 2 before commercializing the ALS treatment?

2. Is Brainstorm planning to stay a development company and license for royalties or will they organically build up into an independent pharma company?

Comment: My gut feeling the royalty model because the worldwide overhead is too great. However, this treatment and technology isn't like traditional pharma where you need a salesforce promoting pills to each insurance carrier trying to get to be the recommended brand. I think the orphan status and patents will likely end up in a place where there is no real competition that can deliver the same or better results.

Can anyone explain why this trades so far below NAV? $1.88 close is only 70% of the NAV of $2.68. It jumped to $2.00 after hours, but in has been trading well below the NAV before this quarter.

It's not just class action lawsuits. Goldman Sachs and JP Morgan are being sued. From law360:

Funds Say Goldman, Others Flubbed $157M SunEdison Buy
By Cara Mannion

Law360, New York (November 15, 2016, 6:19 PM EST) -- Banking heavyweights including Goldman Sachs and JPMorgan underwrote a $157 million SunEdison preferred stock purchase without disclosing the renewable energy company’s hefty loan that hinted at its coming free fall into bankruptcy, according to a suit by two investor funds owned by KKR Corp.
SunEdison Inc. raked in $650 million in an August 2015 preferred stock offering despite already being entrenched in an economic downward spiral, Kearney Investors SA and Powell Investors LP alleged in their suit removed to California federal court Monday. But SunEdison’s executives and a slew of big banks misled investors about the now-bankrupt company’s financial outlook by neglecting to disclose its $169 million loan taken out just one week before the stock offering, according to the suit.

“By misleading plaintiffs and other investors about [SunEdison] while earning lucrative underwriting fees, [SunEdison]’s underwriters are every bit as culpable as [SunEdison] and its officers and directors for the over $100 million of losses that plaintiffs suffered on their investments,” the investor funds said.

SunEdison took out the $169 million loan with a 15 percent interest rate from Goldman Sachs & Co. in August 2015. But the company waited three months to disclose the loan, which was a “glaring red flag” for its future financial woes, the investor funds said.

The funds alleged it’s likely SunEdison got the Goldman loan to pay off a $410 million loan issued in January 2015. Some banks that issued the margin call on the earlier loan were the same banks that underwrote Kearney Investors’ and Powell Investors’ August 2015 stock purchases, according to the complaint. Despite being the very banks whose loans allegedly forced SunEdison to take out the extra $169 million, they still failed to disclose the Goldman loan and cashed in on handsome underwriting fees, the funds said.

“These entities suffered conflicts of interest between their interests as lenders that needed [SunEdison] to remain afloat and underwriters charged with the responsibility of ensuring that [SunEdison] accurately presented its financial condition to the public,” the KKR funds said.

The Goldman loan’s extremely high interest rate, sheer size and reason why it was taken out should have tipped off JPMorgan Securities LLC, Goldman Sachs, Deutsche Bank Securities Inc., Bank of America Merrill Lynch, Morgan Stanley & Co. LLC and MacQuarie Capital Inc. to disclose its existence, the funds argued.

The underwriters also failed to catch SunEdison’s liquidity issues, the funds said. The now-bankrupt company frequently assured investors that it had enough cash flow to fund projects needed to reach growth estimates despite its deep liquidity crisis, according to the suit. It was up to these underwriters to alert investors of issues like this as gatekeepers against securities fraud, according to the suit.

KKR declined to comment Tuesday. The investor funds’ counsel on Tuesday declined to comment past public record.

Goldman Sachs, Morgan Stanley, Merrill Lynch and Macquarie Capital all told Law360 Tuesday that they had no comment. SunEdison also declined to comment on behalf of its executives Tuesday.

JPMorgan and Deutsche Bank were not immediately available for comment Tuesday.

Kearney Investors and Powell Investors are represented by David M. Grable, Andrew J. Rossman, Jordan A. Goldstein and Kimberly E. Carson of Quinn Emanuel Urquhart & Sullivan LLP and Frank J. Broccolo and Mark D. Baute of Baute Crochetiere Gilford LLP.

Peter Blackmore is represented by Gregory Peter Boden and Jessica L. Lewis of Wilmer Cutler Pickering Hale & Dorr LLP. Ahmad Chatila, Martin Truong, Emmanuel Hernandez, Antonio Alvarez, Clayton Daley Jr., Georganne Proctor, Steven Tesoriere, Marshall Turner, James Williams, Randy Zwirn and Brian Wuebbels are all represented by Sara B. Brody of Sidley Austin LLP.

The underwriter defendants are represented by Patrick D. Robbins, Jonah P. Ross, Adam S. Hakki and Daniel C. Lewis of Shearman & Sterling LLP.

The case is Kearny Investors S.A.R.L. et al. v. Goldman Sachs & Co. et al., case number 3:16-cv-06582, in the U.S. District Court for the Northern District of California.

--Editing by Bruce Goldman.

Is the insider owned accurate on iHub? SPLK is showing 98.10% insider owned.

DNS is returning an IP for ascentsolar.com and a whois lookup shows the domain is paid up until 2020, so I think they are having technical difficulties with the website or web host. They are running ColdFusion (old tech) and subpages are returning HTML (like news.cfm). I'm thinking they are just having a technical issue with the web server.

I was hoping for an explanation of the December dates and what the motion itself is referring to in layman's terms. I don't doubt the stock is likely to get cancelled. I think the lawsuits against many of the banks and individuals involved will go on for years. If the free market and very experienced investment banks valued the company well into the multiple billions and it turns out it was worth less than zero, tracing all those dollars will certainly lead to not just unethical, but very likely illegal activity. The saga will likely long outlive the shares.

I saw this, but I think we can use a bit of commentary in layman's terms as to exactly what it means:

SunEdison filed with the U.S. Bankruptcy Court a second motion for entry of an order subordinating and reclassifying claims based on the purchase or sale of securities of the Debtors or their affiliates.

The motion explains, “Consistent with section 510(b) of the Bankruptcy Code and the express terms of the Debtors’ confirmed Plan…the 510(b) Claims should be subordinated to all other creditor claims and reclassified as Class 6 ‘Other Subordinated Claims’ because such claims purport to be based on the purchase or sale of securities of the Debtors or an affiliate of the Debtors or a claim for reimbursement or contribution in connection with such claims. Ordinarily, a party seeking to subordinate a claim must request such relief by way commencing an adversary proceeding, except where, as here, the confirmed Plan expressly provides for the subordination of section 510(b) claims and separately classifies such claims for treatment purposes.”

In addition, “Accordingly, the Debtors file this Motion in an abundance of caution to give express effect to the terms and conditions of the Plan.”

The Court scheduled a December 21, 2017 hearing to consider the motion, with objections due by December 14, 2017.

Why? Because the the KKR lawsuit and its implications and other lawsuits. If GS violated SEC rules, that goes beyond the clients KKR's immediate claims. If kickbacks of any kind occurred during the "fire sale" that will have implications. If the new SUNE is proven to have hidden or lied about assets worldwide, that will have implications.

It's not just about the shares, it's about years of litigation against SUNE, the new SUNE, its officers, some of the other banks involved. etc.

Actually, a few questions would make this a bit more clear:

1. What percentage of yeildco shares (voting and otherwise) were owned by SUNE, it's officers and the banks and other entities that have relationships with those officers?

2. What is the relationship between SUNE officers and the banks, funds, individuals, etc. that bought assets for pennies on the dollar?

3. Did Goldman Sachs violate SEC rules with the secret 15% loan and will KKR win that lawsuit. If so, will SUNE shareholders sue GS?

4. With no chap 7 and complete liquidation, did SUNE lie about the true value of its worldwide assets?

5. Did any executives get any sort of kickback / bribe / compensation from any of the bankruptcy dealings?


And on and on...

What % of the voting shares were owned by SUNE and SUNE management?

Step 1: Put huge money up front for projects with 20 - 30 guaranteed payments

Step 2: Create a wholly owned subsidiary and keep the debt in the parent and the 30 years of future payments in the subsidiary

Step 3: Repeat until debt load is unsustainable. Accept a secret loan at 15% interest from Goldman Sachs

Step 4: Declare bankruptcy for the parent while the subsidiary retains those 30 years of guaranteed payments

Step 5: Sell assets for pennies on the dollar

Step 6: Try to dump shareholders and sell new shares

For this to work, none of the involved parties would have any illegal conflicts of interest, kickbacks, etc.

Shares may be cancelled, but lawsuits will continue for years.

With the price being so low, voluntarily selling may be the larger financial risk if it negatively affects the shareholders' future claims should KKR win against Goldman Sachs or any of the other lawsuits.

Can anyone point to the relevant SEC regulations?

It's not over until the lawsuits are done. Sunedison isn't the only company being sued. Goldman Sachs is. If KKR is correct that they violated SEC rules with the loan, the holders of common shares will have a claim against GS. The chain of events that occurred after what GS did are all in question and subject to litigation if they did indeed violate SEC rules. We'll see.

KKR is suing Goldman Sachs for violating SEC rules regarding the loan they gave to Sunedison. There will be many, many more claims. This won't be truly over for several years.

Does anyone know why this consistently trades at about 2/3 of net asset value?

I'm not sure if it will allow me to post a URL, if not, just search google for sunedison, then filter by news and then by last 24 hours.

https://www.bloomberg.com/news/articles/2017-07-31/goldman-sachs-s-secret-sunedison-loan-at-center-of-kkr-suit

I'm not recommending a buy, but I think the lawsuits against not just Sunedison, but 3rd parties will continue for at least a decade.

From Bloomberg today:

Goldman Sachs Group Inc. in particular, along with Deutsche Bank AG and Morgan Stanley, were involved in a margin call and a “secret” loan that contributed to SunEdison’s collapse, according to lawsuits brought by dozens of investors including KKR & Co. and Pyramid Holdings Inc. The suits, just getting started, are now the main hope for shareholders wiped out by SunEdison’s reorganization plan approved last week.

I chose the first numbers that popped into my head without digging into the financials to get specifics. If you're more familiar, please post the realistic numbers. I have to imagine some of those projects that had 20 - 30 year guaranteed purchases.

The question we need an answer to is if my numbers are acutally the opposite of what happened, where did the money go and how many people are going to jail?

SUNE: I have a guaranteed contract for 10 million a year for 30 years. To get this 300M in income, we need to build a solar facility and we'd like a lona for 10M.

BANK: Here's the 10M.

SUNE: I'm going to create a wholly owned subsidiary and sell the project to myself for 5% of what it's worth. Wow, they fell for that. Let's do this 50 more times, then cook the books to keep all the debt in SUNE and keep all the long term payments in the wholly owned subsidiary and declare bankruptcy.


Thanks what we're looking at.